Modality
Vaccine
MOA
IL-23i
Target
ALK
Pathway
mTOR
SchizophreniaPTSD
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
Oct 2020
→ Apr 2030
Phase 2Current
NCT07379617
895 pts·Schizophrenia
2020-10→2030-04·Active
895 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-234.1y awayPh2 Data· Schizophrenia
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Active
Catalysts
Ph2 Data
2030-04-23 · 4.1y away
Schizophrenia
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07379617 | Phase 2 | Schizophrenia | Active | 895 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Niralucimab | Ionis | Phase 1 | ALK | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR |